Treatment Decisions in Multiple Myeloma

The authors aim to provide a practical framework for navigating treatment decisions in multiple myeloma, addressing the complexities introduced by advancements in therapies and the need for individualized treatment strategies. They emphasize the importance of factors such as cytogenetic and genomic risk stratification, functional fitness, and measurable residual disease status in guiding therapy for newly diagnosed patients and those experiencing relapse. Additionally, the authors advocate for the enrollment of patients in clinical trials to foster ongoing advancements in treatment options.